6MO Single-cell analysis of peripheral blood mononuclear cells reveals therapy outcomes are associated with pre-existing immunity in patients treated with oncolytic adenovirus armed with TNFα and IL2
Year: 2024
Type: article
Abstract: Engineered oncolytic adenovirus Ad5/3-E2F-d24-hTNFa-IRES-hIL2 (TILT-123) has emerged as a promising candidate for clinical translation due to its ability to induce tumor regression and activate host immunity. The phase 1 clinical trial TUNIMO (NCT04695327) assessed the safety of TILT-123 in patients with advanced solid tumors and provided important insights into its therapeutic activity. The presented study aimed to identify immunological markers in peripheral blood capable of predicting treatment outcomes and to elucidate the mechanisms through which TILT-123 modulates immune responses in patients.
Source: Immuno-Oncology Technology
Authors: T. Kudling, D. Bychkov, J. Clubb, S.A. Pakola, V. Arias, E. Jirovec, M. van der Heijden, N. Ojala, D.C.A. Quixabeira, L. Haybout, K. Jalkanen, T.V. Alanko, R. Havunen, S. Sorsa, C. Kistler, A. Kanerva, O.J. Hemminki, J. Santos, V. Cervera-Carrascon, A. Hemminki
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,170
OpenAlex ID: W4405374154